Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”

Detalles Bibliográficos
Autores principales: Behdarvand Dehkordi, Fereshteh, Chehelgerdi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598925/
https://www.ncbi.nlm.nih.gov/pubmed/37880604
http://dx.doi.org/10.1186/s12014-023-09433-w
_version_ 1785125663030640640
author Behdarvand Dehkordi, Fereshteh
Chehelgerdi, Mohammad
author_facet Behdarvand Dehkordi, Fereshteh
Chehelgerdi, Mohammad
author_sort Behdarvand Dehkordi, Fereshteh
collection PubMed
description
format Online
Article
Text
id pubmed-10598925
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105989252023-10-26 Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics” Behdarvand Dehkordi, Fereshteh Chehelgerdi, Mohammad Clin Proteomics Correspondence BioMed Central 2023-10-25 /pmc/articles/PMC10598925/ /pubmed/37880604 http://dx.doi.org/10.1186/s12014-023-09433-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Behdarvand Dehkordi, Fereshteh
Chehelgerdi, Mohammad
Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
title Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
title_full Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
title_fullStr Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
title_full_unstemmed Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
title_short Comment on “Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics”
title_sort comment on “cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. clinical proteomics”
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598925/
https://www.ncbi.nlm.nih.gov/pubmed/37880604
http://dx.doi.org/10.1186/s12014-023-09433-w
work_keys_str_mv AT behdarvanddehkordifereshteh commentoncerebrospinalfluidcamk2alevelsatbaselinepredictlongtermprogressioninmultiplesclerosisclinicalproteomics
AT chehelgerdimohammad commentoncerebrospinalfluidcamk2alevelsatbaselinepredictlongtermprogressioninmultiplesclerosisclinicalproteomics

Ejemplares similares